Sunil Shroff, MD
Clinical Cardiac Electrophysiology · Morris, ILNPI 1437214947
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Johnson & Johnson at 51.1% of the total. Reporting peaked in 2019 at $38,118 and has fallen 88.5% since, to $4,399 in 2025.
Across 598 payments — averaging $243.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$74K
- Abbott$40K
- Biosense Webster, Inc.$10K
- Boston Scientific$4K
- Biotronik Inc.$4K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$4K
- plus $8K from 24 others
What the payments were for
- Consulting fees$35,81725%
- Speaking & faculty fees$81,20356%
- Travel & lodging$13,0129%
- Food & beverage$15,67211%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 79 | $74,400 |
| Abbott | 102 | $40,228 |
| Biosense Webster, Inc. | 38 | $9,614 |
| Boston Scientific | 96 | $4,474 |
| Biotronik Inc. | 11 | $4,398 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 34 | $4,219 |
| Medtronic(2 entities) | 99 | $3,072 |
| Medical Device Business Services, Inc. | 5 | $1,725 |
| Elutia, Inc. | 35 | $749 |
| AOP Health US, LLC | 2 | $663 |
| Inspire Medical Systems, Inc. | 2 | $288 |
| E.r. Squibb & Sons, L.L.C. | 12 | $263 |
| Sanofi-aventis U.S. LLC | 11 | $246 |
| Pfizer | 17 | $237 |
| Novartis | 21 | $228 |
| Kestra Medical Technology Services, Inc. | 6 | $188 |
| Cardiva Medical, Inc. | 3 | $155 |
| AbbVie | 1 | $124 |
| AstraZeneca | 7 | $98 |
| Merck | 4 | $65 |
| Atricure, Inc. | 2 | $45 |
| Lundbeck LLC | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| Novo Nordisk | 1 | $31 |
| Bayer | 1 | $30 |
| Medicomp Inc | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $23 |
| Chiesi USA, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$72,987
- Ensite Cardiac Mapping System$18,427
- EnSite Precision Cardiac Mapping System$15,372
- Carto 3 System$8,348
- Carto Smarttouch$8,348
- Carto CFAE$8,348
- CartoSound$8,348
- LifeVest$3,217
- ADVISOR$2,800
- Carto 3$2,178
- ENSITE PRECISION$1,743
- Micra$1,334
- Rapiblyk$1,326
- EMBLEM$819
- INGEVITY$604
- Acticor 7 VR-T DX$541
- Rivacor 7 DR-T$367
- BioMonitor$367
- Solia$367
- Edora 8 DR-T$367
How this compares
$145,726 in reported general payments places this provider in the 85th percentile of 158 clinical cardiac electrophysiology providers in Illinois.
See all clinical cardiac electrophysiology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 328 | $322,944 |
| XareltoRivaroxaban | 170 | $175,203 |
| EntrestoSacubitril/Valsartan | 83 | $119,806 |
| CorlanorIvabradine Hcl | 13 | $15,750 |
| FarxigaDapagliflozin Propanediol | 14 | $10,707 |
| Ivabradine Hcl | 11 | $9,535 |
| Metoprolol Succinate | 375 | $6,481 |
| Flecainide Acetate | 75 | $4,428 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 171 | $3,260 |
| Nebivolol Hcl | 12 | $1,500 |
| Amlodipine Besylate | 147 | $1,318 |
| Carvedilol | 117 | $1,240 |
| Losartan Potassium | 111 | $1,017 |
| Diltiazem 24hr Er (Xr)Diltiazem Hcl | 15 | $902 |
| Hydralazine Hcl | 37 | $734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $237 | $322,944328 claims |
| Johnson & JohnsonXarelto | $74,400 | $175,203170 claims |
| NovartisEntresto | $228 | $119,80683 claims |
| AstraZenecaFarxiga | $98 | $10,70714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 158 clinical cardiac electrophysiology providers in Illinois.
Other clinical cardiac electrophysiology in Morris
- Mansour RazminiaPalos Heights$927K
- Mark MetzlEvanston$799K
- Roderick TungChicago$795K
- Bradley KnightChicago$661K
- Gaurav UpadhyayChicago$593K
- Henry HuangGeneva$501K
- Kousik KrishnanNaperville$311K
- Hany DemoChicago$297K
- Cash CaseyElmhurst$287K
- Moeen SaleemNaperville$249K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.